Ligand-independent activation of MET through IGF-1/IGF-1R signaling

International Journal of Cancer

Volumn 133, Issue 7, 2013, Pages 1536-1546

  Varkaris, Andreas ^a   Gaur, Sanchaika ^a   Parikh, Nila U ^a   Song, Jian H ^a   Dayyani, Farshid ^a   Jin, Jung Kang ^a   Logothetis, Christopher J ^a   Gallick, Gary E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

cross talk; IGF 1R; MET; prostate cancer; Src

Indexed keywords

DASATINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; VINCULIN;

ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CELL MIGRATION; CONTROLLED STUDY; DRUG TARGETING; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

CROSS TALK; IGF-1R; MET; PROSTATE CANCER; SRC;

ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; ENZYME ACTIVATION; HEPATOCYTE GROWTH FACTOR; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INTEGRINS; LIGANDS; MALE; MICE; NEOPLASM TRANSPLANTATION; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, IGF TYPE 1; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; TRANSCRIPTION, GENETIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84880270856     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28169     Document Type: Article

References (53)

1. Bladt F, Riethmacher D, Isenmann S, et al. Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature 1995; 376: 768-71.
2. Trusolino L, Bertotti A, Comoglio PM,. MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 2010; 11: 834-48.
3. Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997; 16: 68-73.
4. Birchmeier C, Birchmeier W, Gherardi E, et al. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003; 4: 915-25.
5. Available at: http://www.vai.org/Met/Index.aspx.
6. Varkaris A, Corn PG, Gaur S, et al. The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials. Expert Opin Investig Drugs 2011; 20: 1677-84.
7. Liu X, Newton RC, Scherle PA,. Development of c-MET pathway inhibitors. Expert Opin Investig Drugs 2011; 20: 1225-41.
8. Gherardi E, Birchmeier W, Birchmeier C, et al. Targeting MET in cancer: rationale and progress. Nature reviews. Cancer 2012; 12: 89-103.
9. Eder JP, Vande Woude GF, Boerner SA, et al. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 2009; 15: 2207-14.
10. Yap TA, de Bono JS,. Targeting the HGF/c-Met axis: state of play. Mol Cancer Ther 2010; 9: 1077-9.
11. Gao CF, Vande Woude GF,. HGF/SF-Met signaling in tumor progression. Cell Res 2005; 15: 49-51.
12. Fornaro M, Manes T, Languino LR,. Integrins and prostate cancer metastases. Cancer Metastasis Rev 2001; 20: 321-31.
13. Giordano S, Corso S, Conrotto P, et al. The semaphorin 4D receptor controls invasive growth by coupling with Met. Nat Cell Biol 2002; 4: 720-4.
14. Ghatak S, Hascall VC, Markwald RR, et al. Stromal hyaluronan interaction with epithelial CD44 variants promotes prostate cancer invasiveness by augmenting expression and function of hepatocyte growth factor and androgen receptor. J Biol Chem 2010; 285: 19821-32.
15. Lai AZ, Abella JV, Park M,. Crosstalk in Met receptor oncogenesis. Trends Cell Biol 2009; 19: 542-51.
16. Shattuck DL, Miller JK, Carraway KL, III, et al. Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res 2008; 68: 1471-7.
17. Nakajima M, Sawada H, Yamada Y, et al. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 1999; 85: 1894-902.
18. Jo M, Stolz DB, Esplen JE, et al. Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells. J Biol Chem 2000; 275: 8806-11.
19. Dulak AM, Gubish CT, Stabile LP, et al. HGF-independent potentiation of EGFR action by c-Met. Oncogene 2011; 30: 3625-35.
20. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316: 1039-43.
21. Knudsen BS, Gmyrek GA, Inra J, et al. High expression of the Met receptor in prostate cancer metastasis to bone. Urology 2002; 60: 1113-7.
22. Su AI, Welsh JB, Sapinoso LM, et al. Molecular classification of human carcinomas by use of gene expression signatures. Cancer Res 2001; 61: 7388-93.
23. Kimura T, Kuwata T, Ashimine S, et al. Targeting of bone-derived insulin-like growth factor-II by a human neutralizing antibody suppresses the growth of prostate cancer cells in a human bone environment. Clin Cancer Res 2010; 16: 121-9.
24. Papageorgiou E, Pitulis N, Manoussakis M, et al. Rosiglitazone attenuates insulin-like growth factor 1 receptor survival signaling in PC-3 cells. Mol Med 2008; 14: 403-11.
25. Ngo TH, Barnard RJ, Leung PS, et al. Insulin-like growth factor I (IGF-I) and IGF binding protein-1 modulate prostate cancer cell growth and apoptosis: possible mediators for the effects of diet and exercise on cancer cell survival. Endocrinology 2003; 144: 2319-24.
26. Miyake H, Nelson C, Rennie PS, et al. Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3'-kinase pathway. Endocrinology 2000; 141: 2257-65.
27. Maloney EK, McLaughlin JL, Dagdigian NE, et al. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res 2003; 63: 5073-83.
28. Krueckl SL, Sikes RA, Edlund NM, et al. Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model. Cancer Res 2004;64: 8620-9.
29. Windham TC, Parikh NU, Siwak DR, et al. Src activation regulates anoikis in human colon tumor cell lines. Oncogene 2002; 21: 7797-807.
30. Allgayer H, Wang H, Gallick GE, et al. Transcriptional induction of the urokinase receptor gene by a constitutively active Src. Requirement of an upstream motif (-152/-135) bound with Sp1. J Biol Chem 1999; 274: 18428-37.
31. Zhang J, Park SI, Artime MC, et al. AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts. J Clin Investig 2007; 117: 2962-73.
32. Dayyani F, Parikh NU, Varkaris AS, et al. Combined inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathways. PloS One 2012; 7: e51189.
33. Hellawell GO, Turner GD, Davies DR, et al. Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res 2002; 62: 2942-50.
34. Humphrey PA, Zhu X, Zarnegar R, et al. Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol 1995; 147: 386-96.
35. Dai Y, Siemann DW,. Constitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607. BMC Cancer 2012; 12: 198.
36. Montagnani Marelli M, Moretti RM, Procacci P, et al. Insulin-like growth factor-I promotes migration in human androgen-independent prostate cancer cells via the alphavbeta3 integrin and PI3-K/Akt signaling. Int J Oncol 2006; 28: 723-30.
37. Park SI, Zhang J, Phillips KA, et al. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res 2008; 68: 3323-33.
38. Chan JM, Stampfer MJ, Ma J, et al. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 2002; 94: 1099-106.
39. Bauer TW, Somcio RJ, Fan F, et al. Regulatory role of c-Met in insulin-like growth factor-I receptor-mediated migration and invasion of human pancreatic carcinoma cells. Mol Cancer Therap 2006; 5: 1676-82.
40. Bauer TW, Fan F, Liu W, et al. Insulinlike growth factor-I-mediated migration and invasion of human colon carcinoma cells requires activation of c-Met and urokinase plasminogen activator receptor. Ann Surg 2005; 241: 748-56; discussion 56-8.
41. Summy JM, Gallick GE,. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 2003; 22: 337-58.
42. Lara PN, Jr., Longmate J, Evans CP, et al. A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. Anticancer Drugs 2009; 20: 179-84.
43. Araujo JC, Mathew P, Armstrong AJ, et al. Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. Cancer 2012; 118: 63-71.
44. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00744497?term= dasatinib+docetaxel&rank=1.
45. Stofega MR, Yu CL, Wu J, et al. Activation of extracellular signal-regulated kinase (ERK) by mitogenic stimuli is repressed in v-Src-transformed cells. Cell Growth Differ 1997; 8: 113-9.
46. Kato H, Liao Z, Mitsios JV, et al. The primacy of beta1 integrin activation in the metastatic cascade. PloS One 2012; 7: e46576.
47. Lee YC, Jin JK, Cheng CJ, et al. Targeting constitutively activated beta1 integrin inhibits prostate cancer metastasis. Mol Cancer Res 2013;[Epub ahead of print].
48. Wong OG, Nitkunan T, Oinuma I, et al. Plexin-B1 mutations in prostate cancer. Proc Natl Acad Sci USA 2007; 104: 19040-5.
49. Bonine-Summers AR, Aakre ME, Brown KA, et al. Epidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cells. Cancer Biol Ther 2007; 6: 561-70.
50. Bergstrom JD, Westermark B, Heldin NE,. Epidermal growth factor receptor signaling activates met in human anaplastic thyroid carcinoma cells. Exp Cell Res 2000; 259: 293-9.
51. Wu X, Zhou J, Rogers AM, et al. c-Met, epidermal growth factor receptor, and insulin-like growth factor-1 receptor are important for growth in uveal melanoma and independently contribute to migration and metastatic potential. Melanoma Res 2012; 22: 123-32.
52. Reznik TE, Sang Y, Ma Y, et al. Transcription-dependent epidermal growth factor receptor activation by hepatocyte growth factor. Mol Cancer Res 2008; 6: 139-50.
53. Brevet M, Shimizu S, Bott MJ, et al. Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy. J Thorac Oncol 2011; 6: 864-74.